Management of Type 1 Diabetes

Primary Care - Clinics in Office Practice

Volumn 34, Issue 4, 2007, Pages 791-808

  Unger, Jeff ^a  

^a Diabetes and Headache Intervention Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; REACTIVE OXYGEN METABOLITE;

BODY MASS; CLINICAL PRACTICE; DEVELOPING COUNTRY; DIABETIC PATIENT; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; EVENING DOSAGE; FOLLOW UP; GLYCEMIC CONTROL; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

DIABETES MELLITUS, TYPE 1; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RISK FACTORS;

EID: 36649017246     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2007.07.002     Document Type: Review

References (40)

1. Bruno G., Runzo C., Cavallo-Perin P., et al. Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. Diabetes Care 28 (2005) 2613-2619
2. Kukko M., Virtanen S.M., Toivonen A., et al. Geographical variation in risk HLA-DQB1 genotypes for type 1 diabetes and signs of beta-cell autoimmunity in a high-incidence country. Diabetes Care 27 3 (2004) 676-681
3. Seyfert-Margolis V., Gisler T.D., and Asare A.L. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes. Diabetes 55 (2006) 2588-2594
4. Nerup J., Platz P., and Anderssen O.O. HL-A antigens and diabetes mellitus. Lancet 2 (1974) 864-866
5. Bingley P.J., Bonifacio E., Williams J., et al. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46 11 (1997) 1701-1710
6. Notkins A.L., and Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 108 9 (2001) 1247-1252
7. Leslie R.D., Atkinson M.A., and Notkins A.L. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia 42 (1999) 3-14
8. Verge C.F., Gianini R., Pietropaolo M., et al. Prediction of Type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45 (1996) 926-933
9. Turner R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350 (1997) 1288-1293
10. Rosenbloom A.L. Obesity, insulin resistance, beta-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 26 10 (2003) 2954-2956
11. Juneja R., Hirsch I.B., Naik R.G., et al. Islet cell antibodies and glutamic acid decarbosylase antibodies, but not the clinical phenotype, help to identify type 1 (1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 50 (2001) 1008-1013
12. Knip M., and Akerblom H.K. Environmental factors in the pathogenesis of type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 107 (1999) S93-S100
13. Morgan C.L., Currie C.L., and Peters J.R. Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care 23 (2000) 1103-1107
14. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
16. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
17. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care 30 (2007) S9-S10
18. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 (2000) 381-389
19. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 Suppl 25 (2005) 2643-2653
20. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348 (2003) 2294-2903
21. Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290 (2003) 2159-2167
22. Genuth S. Insights from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 12 Suppl 1 (2006) 34-41
23. ACE/AACE Diabetes Recommendations Implementation Conference. Road map for the prevention and treatment of type two diabetes. Available at: http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf-sear ch5%22AACE%20Roadmap%22. Accessed August 28, 2006.
24. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 Suppl 1 (2007) 10
25. Unger J. Managing type 2 diabetes in adults. In: Unger J. (Ed). Diabetes management in primary care (2007), Lippincott, Williams and Wilkins, Philadelphia 118-191
26. Briscoe V.J., Davis S.N., and Vaness J. Hypoglycemia in type 1 and type 2 diabetes. Physiology, pathophysiology and management. Clin Diabetes 24 (2006) 115-121
27. Kruszynska Y.T., Home P.D., Hanning I., et al. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia 30 (1987) 16-21
28. Home P.D., Lindholm A., Hylleberg B., et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 21 (1998) 1904-1909
29. Gale E.A. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med 17 (2000) 209-214
30. Bolli G.B. Insulin treatment in type 1 diabetes. Endocr Pract 12 Suppl 1 (2006) 105-109
31. Goldman-Levine J.D., and Lee K.W. Insulin detemir-a new basal insulin analogue. Ann Pharmacother 393 (2005) 502-507
32. Heise T., Nosek L., Biilmann Rønn B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
33. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 81-820
34. Risso A., Mercuri F., Quagliaro L., et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 281 (2001) E924-E930
35. McGiull J.B., Cole T.G., Nowatzke W., et al. Circulating 1,5-anhydroglucitorl levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the glycomark assay. Diabetes Care 8 (2004) 1859-1865
36. Kishimoto M., Yamasaki Y., Kubota M., et al. 1,5-anhydro-d-glucitol evaluated daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18 (1995) 1156-1159
37. Rave K., Bott S., Heinemann L., et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28 (2005) 1077-1082
38. Unger J. Novel insulin replacement. diabetes consultation collection. Emerg med Suppl (2006) 10-14
39. Riddle M.C., Rosenstock J., and Gerich J. Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
40. Meneghini L, Koehnen C, Weng W, et al. The usage of a simplified self-titration dosing guideline for insulin detemir in patients type 2 diabetes-results of the 303 Algorithm Study. Presented at the 67th Annual Meeting of the American Diabetes Association. Chicago, June 23-27, 2007.